The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Dissecting the role of mTOR: Lessons from mTOR inhibitors
Open accessAbstract
Recent years have observed significant advances in our understanding of how the serine/threonine kinase target of rapamycin (TOR) controls key cellular processes such as cell survival, growth and proliferation. Consistent with its role in cell proliferation, the mTOR pathway is frequently hyperactivated in a number of human malignancies and is thus considered to be an attractive target for anti-cancer therapy. Rapamycin and its analogs (rapalogs) function as allosteric inhibitors of mTORC1 and are currently used in the treatment of advanced renal cell carcinoma. Rapamycin and its derivatives bind to the small immunophilin FKBP12 to inhibit mTORC1 signalling through a poorly understood mechanism. Rapamycin/FKBP12 efficiently inhibit some, but not all, functions of mTOR and hence much interest has been placed in the development of drugs that target the kinase activity of mTOR directly. Several novel active-site inhibitors of mTOR, which inhibit both mTORC1 and mTORC2, were developed in the last year. In this manuscript, we provide a brief outline of our current understanding of the mTOR signalling pathway and review the molecular underpinnings of the action of rapamycin and novel active-site mTOR inhibitors as well as potential advantages and caveats associated with the use of these drugs in the treatment of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
Self-citationTSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914
Regulation of Translation Initiation in Eukaryotes: Mechanisms and Biological Targets
Sonenberg, N., & Hinnebusch, A. G. (2009) · Cell · doi:10.1016/j.cell.2009.01.042 · Cited by 3,304
Self-citationKim, D.-H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 2,986
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
Targeting the phosphoinositide 3-kinase pathway in cancer
Liu, P., Cheng, H., Roberts, T. M., & Zhao, J. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2926 · Cited by 2,721
Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
Molecular mechanisms of mTOR-mediated translational control
Ma, X. M., & Blenis, J. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2672 · Cited by 2,558
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
eIF4 Initiation Factors: Effectors of mRNA Recruitment to Ribosomes and Regulators of Translation
Gingras, A.-C., Raught, B., & Sonenberg, N. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.913 · Cited by 2,121
Self-citationMammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive
Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Rüegg, M. A., Hall, A., & Hall, M. N. (2004) · Nature Cell Biology · doi:10.1038/ncb1183 · Cited by 2,114
Nutrient-dependent mTORC1 Association with the ULK1–Atg13–FIP200 Complex Required for Autophagy
Hosokawa, N., Hara, T., Kaizuka, T., Kishi, C., Takamura, A., Miura, Y., Iemura, S.-I., Natsume, T., Takehana, K., Yamada, N., et al. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-12-1248 · Cited by 2,076
ULK-Atg13-FIP200 Complexes Mediate mTOR Signaling to the Autophagy Machinery
Jung, C. H., Jun, C. B., Ro, S.-H., Kim, Y.-M., Otto, N. M., Cao, J., Kundu, M., & Kim, D.-H. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-12-1249 · Cited by 2,025
Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action
Hara, K., Maruki, Y., Long, X., Yoshino, K.-I., Oshiro, N., Hidayat, S., Tokunaga, C., Avruch, J., & Yonezawa, K. (2002) · Cell · doi:10.1016/s0092-8674(02)00833-4 · Cited by 1,810
Thoreen, C. C., Kang, S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., Reichling, L. J., Sim, T., Sabatini, D. M., & Gray, N. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900301200 · Cited by 1,803
mTOR controls mitochondrial oxidative function through a YY1–PGC-1α transcriptional complex
Cunningham, J. T., Rodgers, J. T., Arlow, D. H., Vazquez, F., Mootha, V. K., & Puigserver, P. (2007) · Nature · doi:10.1038/nature06322 · Cited by 1,488
ULK1·ATG13·FIP200 Complex Mediates mTOR Signaling and Is Essential for Autophagy
Ganley, I. G., Lam, D. H., Wang, J., Ding, X., Chen, S., & Jiang, X. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900573200 · Cited by 1,447
SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth
Porstmann, T., Santos, C. R., Griffiths, B., Cully, M., Wu, M., Leevers, S., Griffiths, J. R., Chung, Y.-L., & Schulze, A. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.07.007 · Cited by 1,413
Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S. Y., Huang, Q., Qin, J., & Su, B. (2006) · Cell · doi:10.1016/j.cell.2006.08.033 · Cited by 1,410
Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism
Gingras, A.-C., Gygi, S. P., Raught, B., Polakiewicz, R. D., Abraham, R. T., Hoekstra, M. F., Aebersold, R., & Sonenberg, N. (1999) · Genes & Development · doi:10.1101/gad.13.11.1422 · Cited by 1,343
Self-citationmTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322
Pause, A., Belsham, G. J., Gingras, A.-C., Donzé, O., Lin, T.-A., Lawrence, J. C., & Sonenberg, N. (1994) · Nature · doi:10.1038/371762a0 · Cited by 1,239
Self-citationThe TSC1–TSC2 complex: a molecular switchboard controlling cell growth
Huang, J., & Manning, B. D. (2008) · Biochemical Journal · doi:10.1042/bj20080281 · Cited by 1,237
PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase
Sancak, Y., Thoreen, C. C., Peterson, T. R., Lindquist, R. A., Kang, S. A., Spooner, E., Carr, S. A., & Sabatini, D. M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.03.003 · Cited by 1,236
The coordinate regulation of the p53 and mTOR pathways in cells
Feng, Z., Zhang, H., Levine, A. J., & Jin, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502857102 · Cited by 1,235
Peterson, T. R., Laplante, M., Thoreen, C. C., Sancak, Y., Kang, S. A., Kuehl, W. M., Gray, N. S., & Sabatini, D. M. (2009) · Cell · doi:10.1016/j.cell.2009.03.046 · Cited by 1,202
Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40
Haar, E. V., Lee, S.-I., Bandhakavi, S., Griffin, T. J., & Kim, D.-H. (2007) · Nature Cell Biology · doi:10.1038/ncb1547 · Cited by 1,190
Autophagy and signaling: their role in cell survival and cell death
Codogno, P., & Meijer, A. J. (2005) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401751 · Cited by 1,092
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Feldman, M. E., Apsel, B., Uotila, A., Loewith, R., Knight, Z. A., Ruggero, D., & Shokat, K. M. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000038 · Cited by 1,082
The LKB1 tumor suppressor negatively regulates mTOR signaling
Shaw, R. J., Bardeesy, N., Manning, B. D., Lopez, L., Kosmatka, M., DePinho, R. A., & Cantley, L. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.007 · Cited by 1,077
Current development of mTOR inhibitors as anticancer agents
Faivre, S., Kroemer, G., & Raymond, E. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2062 · Cited by 1,000
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
Neshat, M. S., Mellinghoff, I. K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J. J., Wu, H., & Sawyers, C. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171076798 · Cited by 969
García-Martínez, J. M., & Alessi, D. R. (2008) · Biochemical Journal · doi:10.1042/bj20081668 · Cited by 907
Hierarchical phosphorylation of the translation inhibitor 4E-BP1
Gingras, A.-C., Raught, B., Gygi, S. P., Niedzwiecka, A., Miron, M., Burley, S. K., Polakiewicz, R. D., Wyslouch-Cieszynska, A., Aebersold, R., & Sonenberg, N. (2001) · Genes & Development · doi:10.1101/gad.912401 · Cited by 883
Self-citationTee, A. R., Fingar, D. C., Manning, B. D., Kwiatkowski, D. J., Cantley, L. C., & Blenis, J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202476899 · Cited by 827
Choo, A. Y., Yoon, S.-O., Kim, S. G., Roux, P. P., & Blenis, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809136105 · Cited by 810
Alessi, D. R., Deak, M., Casamayor, A., Barry Caudwell, F., Morrice, N., Norman, D. G., Gaffney, P., Reese, C. B., MacDougall, C. N., Harbison, D., et al. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00336-8 · Cited by 737
eIF-4E expression and its role in malignancies and metastases
De Benedetti, A., & Graff, J. R. (2004) · Oncogene · doi:10.1038/sj.onc.1207545 · Cited by 728
A complex interplay between Akt, TSC2 and the two mTOR complexes
Huang, J., & Manning, B. D. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370217 · Cited by 724
mSin1 Is Necessary for Akt/PKB Phosphorylation, and Its Isoforms Define Three Distinct mTORC2s
Frias, M. A., Thoreen, C. C., Jaffe, J. D., Schroder, W., Sculley, T., Carr, S. A., & Sabatini, D. M. (2006) · Current Biology · doi:10.1016/j.cub.2006.08.001 · Cited by 695
The mRNA 5′ cap-binding protein eIF4E and control of cell growth
Sonenberg, N., & Gingras, A.-C. (1998) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(98)80150-6 · Cited by 673
Self-citationmTOR·RICTOR Is the Ser473 Kinase for Akt/Protein Kinase B in 3T3-L1 Adipocytes
Hresko, R. C., & Mueckler, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508361200 · Cited by 635
Schieke, S. M., Phillips, D., McCoy, J. P., Aponte, A. M., Shen, R.-F., Balaban, R. S., & Finkel, T. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603536200 · Cited by 623
mTOR, translation initiation and cancer
Mamane, Y., Petroulakis, E., LeBacquer, O., & Sonenberg, N. (2006) · Oncogene · doi:10.1038/sj.onc.1209888 · Cited by 607
Self-citationThe Pharmacology of mTOR Inhibition
Guertin, D. A., & Sabatini, D. M. (2009) · Science Signaling · doi:10.1126/scisignal.267pe24 · Cited by 568
Chen, J., Zheng, X. F., Brown, E. J., & Schreiber, S. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.4947 · Cited by 556
An expanding role for mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.06.007 · Cited by 523
Land, S. C., & Tee, A. R. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611782200 · Cited by 507
Mayer, C., Zhao, J., Yuan, X., & Grummt, I. (2004) · Genes & Development · doi:10.1101/gad.285504 · Cited by 505
Raymond, E., Alexandre, J., Faivre, S., Vera, K., Materman, E., Boni, J., Leister, C., Korth-Bradley, J., Hanauske, A., & Armand, J.-P. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.116 · Cited by 499
PRAS40 Regulates mTORC1 Kinase Activity by Functioning as a Direct Inhibitor of Substrate Binding
Wang, L., Harris, T. E., Roth, R. A., & Lawrence, J. C. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702376200 · Cited by 494
Yokogami, K., Wakisaka, S., Avruch, J., & Reeves, S. A. (2000) · Current Biology · doi:10.1016/s0960-9822(99)00268-7 · Cited by 469
Identification of Protor as a novel Rictor-binding component of mTOR complex-2
Pearce, L. R., Huang, X., Boudeau, J., Pawłowski, R., Wullschleger, S., Deak, M., Ibrahim, A. F. M., Gourlay, R., Magnuson, M. A., & Alessi, D. R. (2007) · Biochemical Journal · doi:10.1042/bj20070540 · Cited by 464
Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
García-Martínez, J. M., Moran, J., Clarke, R. G., Gray, A., Cosulich, S. C., Chresta, C. M., & Alessi, D. R. (2009) · Biochemical Journal · doi:10.1042/bj20090489 · Cited by 455
Kim, J. E., & Chen, J. (2004) · Diabetes · doi:10.2337/diabetes.53.11.2748 · Cited by 454
eIF4E – from translation to transformation
Mamane, Y., Petroulakis, E., Rong, L., Yoshida, K., Ler, L. W., & Sonenberg, N. (2004) · Oncogene · doi:10.1038/sj.onc.1207549 · Cited by 449
Self-citationYu, K., Toral-Barza, L., Discafani, C., Zhang, W. G., Skotnicki, J., Frost, P., & Gibbons, J. J. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080249 · Cited by 420
Koromilas, A. E., Lazaris-Karatzas, A., & Sonenberg, N. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05508.x · Cited by 419
Self-citationmTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice
Guertin, D. A., Stevens, D. M., Saitoh, M., Kinkel, S., Crosby, K., Sheen, J.-H., Mullholland, D. J., Magnuson, M. A., Wu, H., & Sabatini, D. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.017 · Cited by 355
Yu, K., Toral-Barza, L., Shi, C., Zhang, W.-G., Lucas, J., Shor, B., Kim, J., Verheijen, J., Curran, K., Malwitz, D. J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0299 · Cited by 330
eIF4E expression in tumors: its possible role in progression of malignancies
De Benedetti, A., & Harris, A. L. (1999) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(98)00132-0 · Cited by 324
Oshiro, N., Takahashi, R., Yoshino, K.-I., Tanimura, K., Nakashima, A., Eguchi, S., Miyamoto, T., Hara, K., Takehana, K., Avruch, J., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702636200 · Cited by 318
Dissociation of raptor from mTOR is a mechanism of rapamycin‐induced inhibition of mTOR function
Oshiro, N., Yoshino, K., Hidayat, S., Tokunaga, C., Hara, K., Eguchi, S., Avruch, J., & Yonezawa, K. (2004) · Genes to Cells · doi:10.1111/j.1356-9597.2004.00727.x · Cited by 308
PRAS40 and PRR5-Like Protein Are New mTOR Interactors that Regulate Apoptosis
Thedieck, K., Polak, P., Kim, M. L., Molle, K. D., Cohen, A., Jenö, P., Arrieumerlou, C., & Hall, M. N. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001217 · Cited by 296
Determinants of Rapamycin Sensitivity in Breast Cancer Cells
Noh, W.-C., Mondesire, W. H., Peng, J., Jian, W., Zhang, H., Dong, J., Mills, G. B., Hung, M.-C., & Meric-Bernstam, F. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0043 · Cited by 285
Mita, M. M., Mita, A. C., Chu, Q. S., Rowinsky, E. K., Fetterly, G. J., Goldston, M., Patnaik, A., Mathews, L., Ricart, A. D., Mays, T., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0345 · Cited by 273
Raught, B. (2000) · The EMBO Journal · doi:10.1093/emboj/19.3.434 · Cited by 270
Petricoin, E. F., Espina, V., Araujo, R. P., Midura, B., Yeung, C., Wan, X., Eichler, G. S., Johann, D. J., Qualman, S., Tsokos, M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1344 · Cited by 250
Fonseca, B. D., Smith, E. M., Lee, V. H.-Y., MacKintosh, C., & Proud, C. G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704406200 · Cited by 240
Self-citationRosner, M., & Hengstschlager, M. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn192 · Cited by 233
Insulin-stimulated phosphorylation of lipin mediated by the mammalian target of rapamycin
Huffman, T. A., Mothe-Satney, I., & Lawrence, J. C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.022634399 · Cited by 215
Choo, A. Y., & Blenis, J. (2009) · Cell Cycle · doi:10.4161/cc.8.4.7659 · Cited by 210
Topisirovic, I., Guzman, M. L., McConnell, M. J., Licht, J. D., Culjkovic, B., Neering, S. J., Jordan, C. T., & Borden, K. L. B. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.24.8992-9002.2003 · Cited by 206
Self-citationRojo, F., Najera, L., Lirola, J., Jiménez, J., Guzmán, M., Sabadell, M. D., Baselga, J., & Cajal, S. R. Y. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1560 · Cited by 205
Woo, S.-Y., Kim, D.-H., Jun, C.-B., Kim, Y.-M., Haar, E. V., Lee, S.-I., Hegg, J. W., Bandhakavi, S., Griffin, T. J., & Kim, D.-H. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704343200 · Cited by 202
Multiple genes at 17q23 undergo amplification and overexpression in breast cancer.
Barlund, M. T., Monni, O. M., Kononen, J., Cornelison, R., Torhorst, J. K. H., Sauter, G., OLLI-P, K., & Kallioniemi, A. H. (2000) · PubMed · Cited by 199
Castellvi, J., Garcia, A., Rojo, F., Ruiz‐Marcellan, C., Gil, A., Baselga, J., & Ramon y Cajal, S. (2006) · Cancer · doi:10.1002/cncr.22195 · Cited by 177
mTOR signaling: implications for cancer and anticancer therapy
Petroulakis, E., Mamane, Y., Le Bacquer, O., Shahbazian, D., & Sonenberg, N. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602902 · Cited by 170
Self-citationp53-Dependent Translational Control of Senescence and Transformation via 4E-BPs
Petroulakis, E., Parsyan, A. E., Dowling, R. J. O., Bacquer, O. L., Martineau, Y., Bidinosti, M., Larsson, O. S., Alain, T., Rong, L., Mamane, Y., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.025 · Cited by 135
Self-citationShor, B., Zhang, W., Toral‐Barza, L., Lucas, J., Abraham, R. T., Gibbons, J. J., & Yu, K. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6487 · Cited by 131
The Rapamycin-Binding Domain Governs Substrate Selectivity by the Mammalian Target of Rapamycin
McMahon, L. P., Choi, K. M., Lin, T.-A., Abraham, R. T., & Lawrence, J. C. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.21.7428-7438.2002 · Cited by 113
Determinants of Sensitivity and Resistance to Rapamycin-Chemotherapy Drug Combinations In vivo
Wendel, H., Malina, A., Zhao, Z., Zender, L., Kogan, S. C., Cordon‐Cardo, C., Pelletier, J., & Lowe, S. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0419 · Cited by 108
The FKBP12‐rapamycin‐associated protein (FRAP) is a CLIP‐170 kinase
Choi, J. H., Bertram, P. G., Drenan, R. M., Carvalho, J. J., Zhou, H. H., & Zheng, X.-F. (2002) · EMBO Reports · doi:10.1093/embo-reports/kvf197 · Cited by 98
Dilling, M. B., Germain, G. S., Dudkin, L., Jayaraman, A. L., Zhang, X., Harwood, F. C., & Houghton, P. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110782200 · Cited by 98
Kapoor, A., & Figlin, R. A. (2009) · Cancer · doi:10.1002/cncr.24409 · Cited by 80
Current Status and Challenges Associated with Targeting mTOR for Cancer Therapy
Dowling, R. J. O., Pollak, M., & Sonenberg, N. (2009) · BioDrugs · doi:10.2165/00063030-200923020-00002 · Cited by 55
Self-citationFonseca, B. D., Lee, V. H.-Y., & Proud, C. G. (2008) · Biochemical Journal · doi:10.1042/bj20071001 · Cited by 32
Self-citationCharacterization of the Phosphoproteins and Protein Kinase Activity in mTOR Immunoprecipitates
Nishiuma, T., Hara, K., Tsujishita, Y., Kaneko, K., Shii, K., & Yonezawa, K. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9671 · Cited by 27
Cited by
Hsu, P. P., Kang, S. A., Rameseder, J., Zhang, Y., Ottina, K. A., Lim, D., Peterson, T. R., Choi, Y., Gray, N. S., Yaffe, M. B., et al. (2011) · Science · doi:10.1126/science.1199498 · Cited by 1,084
Panwar, V., Singh, A., Bhatt, M., Tonk, R. K., Azizov, S., Raza, A. S., Sengupta, S., Kumar, D., & Garg, M. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01608-z · Cited by 967
mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
Zou, Z., Tao, T., Li, H., & Zhu, X. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00396-1 · Cited by 927
PTEN loss in the continuum of common cancers, rare syndromes and mouse models
Hollander, M. C., Blumenthal, G. M., & Dennis, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3037 · Cited by 794
The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers
Paplomata, E., & O’Regan, R. (2014) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014530023 · Cited by 593
Metadata
- Authors
- Dowling, R. J. O., Topisirovic, I., Fonseca, B. D., & Sonenberg, N.
- Venue
- Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
- Publisher
- Elsevier BV
- Published
- 2010-03
- Volume
- 1804
- Issue
- 3
- Pages
- 433-439
- ISSN
- 1570-9639 (ISSN-L)
- OpenAlex
- W2080127092
- Cited by
- 454
- References
- 89
- FWCI
- 10.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.